Cargando…

Patient experience with non-invasive prenatal testing (NIPT) as a primary screen for aneuploidy in the Netherlands

BACKGROUND: Non-invasive prenatal testing (NIPT) as a screening method for trisomy 21 and other chromosomal abnormalities has been adopted widely across the globe. However, while many clinical validation studies have been performed, less is known regarding the patient experience with NIPT. This stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Kristalijn, Syanni A., White, Karen, Eerbeek, Deanna, Kostenko, Emilia, Grati, Francesca Romana, Bilardo, Caterina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585792/
https://www.ncbi.nlm.nih.gov/pubmed/36266611
http://dx.doi.org/10.1186/s12884-022-05110-2
_version_ 1784813568653262848
author Kristalijn, Syanni A.
White, Karen
Eerbeek, Deanna
Kostenko, Emilia
Grati, Francesca Romana
Bilardo, Caterina M.
author_facet Kristalijn, Syanni A.
White, Karen
Eerbeek, Deanna
Kostenko, Emilia
Grati, Francesca Romana
Bilardo, Caterina M.
author_sort Kristalijn, Syanni A.
collection PubMed
description BACKGROUND: Non-invasive prenatal testing (NIPT) as a screening method for trisomy 21 and other chromosomal abnormalities has been adopted widely across the globe. However, while many clinical validation studies have been performed, less is known regarding the patient experience with NIPT. This study explored how individuals experience NIPT in a pre- and post-test setting, where NIPT is broadly available as a primary screening method with the option of reporting beyond common trisomies. METHODS: Participants were recruited using social media with a strategy designed to select individuals who had the option to have NIPT as part of the TRIDENT-2 study (In the Netherlands, NIPT is only available within the TRIDENT studies executed by the NIPT consortium. This research was done independently from the NIPT consortium.) in the Netherlands. The study used online questionnaires and semi-structured interviews. Both were developed around a patient experience framework consisting of seven themes: information, patient as active participant, responsiveness of services, lived experience, continuity of care and relationships, communication, and support. RESULTS: Overall, 4539 questionnaire responses were analyzed and 60% of the respondents had experienced NIPT. Of those, 1.7% received a high-risk result for trisomy or another chromosomal copy number variant (referred to as an “additional finding”). Overall, participants felt they had received sufficient information and had control over their decision regarding whether or not to choose NIPT. The vast majority of respondents who had NIPT were positive about their experience and would use it again. Those with results showing an increased probability for trisomy or additional findings were more likely to report negative feelings such as tension and anxiety, and less likely to feel that they had been sufficiently prepared for the implications of their results. CONCLUSIONS: The patient experience with first-tier NIPT in the Netherlands was largely positive. Areas for improvement included counseling on the implications of screening and the different possible outcomes of NIPT, including additional findings that may be uncovered by expanding NIPT beyond the common trisomies. The experiences reported in this study may be useful for other countries intending to implement NIPT.
format Online
Article
Text
id pubmed-9585792
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95857922022-10-22 Patient experience with non-invasive prenatal testing (NIPT) as a primary screen for aneuploidy in the Netherlands Kristalijn, Syanni A. White, Karen Eerbeek, Deanna Kostenko, Emilia Grati, Francesca Romana Bilardo, Caterina M. BMC Pregnancy Childbirth Research BACKGROUND: Non-invasive prenatal testing (NIPT) as a screening method for trisomy 21 and other chromosomal abnormalities has been adopted widely across the globe. However, while many clinical validation studies have been performed, less is known regarding the patient experience with NIPT. This study explored how individuals experience NIPT in a pre- and post-test setting, where NIPT is broadly available as a primary screening method with the option of reporting beyond common trisomies. METHODS: Participants were recruited using social media with a strategy designed to select individuals who had the option to have NIPT as part of the TRIDENT-2 study (In the Netherlands, NIPT is only available within the TRIDENT studies executed by the NIPT consortium. This research was done independently from the NIPT consortium.) in the Netherlands. The study used online questionnaires and semi-structured interviews. Both were developed around a patient experience framework consisting of seven themes: information, patient as active participant, responsiveness of services, lived experience, continuity of care and relationships, communication, and support. RESULTS: Overall, 4539 questionnaire responses were analyzed and 60% of the respondents had experienced NIPT. Of those, 1.7% received a high-risk result for trisomy or another chromosomal copy number variant (referred to as an “additional finding”). Overall, participants felt they had received sufficient information and had control over their decision regarding whether or not to choose NIPT. The vast majority of respondents who had NIPT were positive about their experience and would use it again. Those with results showing an increased probability for trisomy or additional findings were more likely to report negative feelings such as tension and anxiety, and less likely to feel that they had been sufficiently prepared for the implications of their results. CONCLUSIONS: The patient experience with first-tier NIPT in the Netherlands was largely positive. Areas for improvement included counseling on the implications of screening and the different possible outcomes of NIPT, including additional findings that may be uncovered by expanding NIPT beyond the common trisomies. The experiences reported in this study may be useful for other countries intending to implement NIPT. BioMed Central 2022-10-20 /pmc/articles/PMC9585792/ /pubmed/36266611 http://dx.doi.org/10.1186/s12884-022-05110-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kristalijn, Syanni A.
White, Karen
Eerbeek, Deanna
Kostenko, Emilia
Grati, Francesca Romana
Bilardo, Caterina M.
Patient experience with non-invasive prenatal testing (NIPT) as a primary screen for aneuploidy in the Netherlands
title Patient experience with non-invasive prenatal testing (NIPT) as a primary screen for aneuploidy in the Netherlands
title_full Patient experience with non-invasive prenatal testing (NIPT) as a primary screen for aneuploidy in the Netherlands
title_fullStr Patient experience with non-invasive prenatal testing (NIPT) as a primary screen for aneuploidy in the Netherlands
title_full_unstemmed Patient experience with non-invasive prenatal testing (NIPT) as a primary screen for aneuploidy in the Netherlands
title_short Patient experience with non-invasive prenatal testing (NIPT) as a primary screen for aneuploidy in the Netherlands
title_sort patient experience with non-invasive prenatal testing (nipt) as a primary screen for aneuploidy in the netherlands
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585792/
https://www.ncbi.nlm.nih.gov/pubmed/36266611
http://dx.doi.org/10.1186/s12884-022-05110-2
work_keys_str_mv AT kristalijnsyannia patientexperiencewithnoninvasiveprenataltestingniptasaprimaryscreenforaneuploidyinthenetherlands
AT whitekaren patientexperiencewithnoninvasiveprenataltestingniptasaprimaryscreenforaneuploidyinthenetherlands
AT eerbeekdeanna patientexperiencewithnoninvasiveprenataltestingniptasaprimaryscreenforaneuploidyinthenetherlands
AT kostenkoemilia patientexperiencewithnoninvasiveprenataltestingniptasaprimaryscreenforaneuploidyinthenetherlands
AT gratifrancescaromana patientexperiencewithnoninvasiveprenataltestingniptasaprimaryscreenforaneuploidyinthenetherlands
AT bilardocaterinam patientexperiencewithnoninvasiveprenataltestingniptasaprimaryscreenforaneuploidyinthenetherlands